• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Inozyme Pharma Inc (NQ: INZY )

    5.830 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 5.830
    Bid (Size) 5.610 (1)
    Ask (Size) 6.900 (2)
    Prev. Close 5.830
    Today's Range 5.830 - 5.830
    52wk Range 2.689 - 7.795
    Shares Outstanding 61,729,666
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look'
    Stifel initiates coverage on Inozyme Pharma with a Buy rating and a $16 price target, highlighting INZ-701's potential to treat rare diseases like ENPP1 and ABCC6 deficiencies. 
    Via Benzinga
    This AutoNation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
    Via Benzinga

    Performance

    YTD
    +34.64%
    +34.64%
    1 Month
    +19.96%
    +19.96%
    3 Month
    +32.50%
    +32.50%
    6 Month
    +2.46%
    +2.46%
    1 Year
    +42.54%
    +42.54%

    More News

    Read More
    Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Inozyme Pharma: Q4 Earnings Insights
    Via Benzinga
    ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    INZY Stock Earnings: Inozyme Pharma Misses EPS for Q2 2024
    Via InvestorPlace
    Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma to Present at the Jefferies Global Healthcare Conference
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    INZY Stock Earnings: Inozyme Pharma Misses EPS for Q1 2024
    Via InvestorPlace
    Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Top 5 Health Care Stocks That May Plunge In March
    Via Benzinga
    Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
    From Inozyme Pharma Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.